

FORM PTO-1449 (REV.7-80)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C8	APPLICATION NO. 09/167,516
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			APPLICANTS Martin A. Cheever and Mary L. Disis			
			FILING DATE October 6, 1998		GROUP ART UNIT 1642	

OCT 18 1999

U.S. PATENT DOCUMENTS

*EXAMINER'S INITIAL	SEARCH & TRA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KAC	AA	3,766,162	10/1973	Spector	260	112.R	
	AB	3,791,932	02/1974	Schuurs et al.	195	103.5R	
	AC	3,817,837	06/1974	Rubenstein et al.	195	103.5R	
	AD	3,850,752	11/1974	Schuurs et al.	195	103.5R	
	AE	3,901,654	08/1975	Gross	23	230.B	
	AF	3,935,074	01/1976	Rubenstein et al.	195	103.5R	
	AG	3,984,533	10/1976	Uzgiris	424	12	
	AH	3,996,345	12/1976	Ullman et al.	424	12	
	AI	4,034,074	07/1977	Miles	424	1	
	AJ	4,098,876	07/1978	Piasio et al.	424	1	
↓	AK	4,233,402	11/1980	Maggio et al.	435	7	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
KAC	AL	WO 90/14357	11/1990	PCT		
KAC	AM	WO 91/02062	02/1991	PCT		
	AN					
	AO					
	AP					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AQ	Alper et al., "The Presence of c-erbB-2 Gene Product-related Protein in Culture Medium Conditioned by Breast Cancer Cell Line SK-BR-3," <i>Cell Growth & Differentiation</i> 1:591-599, 1990.
KAC	AR	Bargmann et al., "The neu oncogene encodes an epidermal growth factor receptor-related protein," <i>Nature</i> 319:226-230, 1986.
KAC	AS	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185(^HER2) Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer," <i>Journal of Clinical Oncology</i> 14(3): 737-744, 1996.

EXAMINER

Karen A. Gamella

DATE CONSIDERED

7/3/01

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.448C8APPLICATION NO.
09/167,516

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE

October 6, 1998

GROUP ART UNIT

1642

OCT 18 1998

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KAC	AA 4,452,901	06/1984	Gordon et al.	436	506	7/3/01
KAC	AB 5,320,947	06/1994	Cheever et al.	435	29	7/3/01
KAC	AC 5,401,638	03/1995	Carney et al.	435	7.23	7/3/01
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AQ		Ben-Mahrez et al., "Circulating Antibodies Against C-myc Oncogene Product In Sera Of Colorectal Cancer Patients," <i>Int. J. Cancer</i> 46: 35-38, 1990.
KAC	AR		Ben-Mahrez et al., "Detection of circulating antibodies against c-myc protein in cancer patient sera," <i>Br. J. Cancer</i> 57: 529-534, 1988.
KAC	AS		Bishop and Orosz, "Limiting Dilution Analysis For Alloreactive, TCGF-Secretory T Cells. Two Related LDA Methods That Discriminate Between Unstimulated Precursor T Cells and In Vivo-Alloactivated T Cells," <i>Transplantation</i> 47(4): 671-677, 1989.

EXAMINER

Karen A. Gamella

DATE CONSIDERED

7/3/01

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C8	APPLICATION NO. 09/167,516
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			APPLICANTS Martin A. Cheever and Mary L. Disis			
			FILING DATE October 6, 1998	GROUP ART UNIT 1642		
OCT 18 1999 U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS
FILING DATE IF APPROPRIATE						
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION
						YES NO
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>						
KAC	AA	Bodmer, W., "T-Cell Immune Responses to Cancer--A New Look," <i>Human Immunology</i> 30:259-261, 1991.				
	AB	Bowen-Pope et al., "Production of platelet-derived growth factor-like molecules and reduced expression of platelet-derived growth factor receptors accompany transformation by a wide spectrum of agents," <i>Proc. Natl. Acad. Sci. USA</i> 81: 2396-2400, 1984.				
	AC	Brooks et al., "Human lymphocyte markers defined by antibodies derived from somatic cell-hybrids," <i>Clin. Exp. Immunol.</i> 39: 477-485, 1980.				
	AD	Brown et al., "Protein Antigens of Normal and Malignant Human Cells Identified by Immunoprecipitation with Monoclonal Antibodies," <i>Journal of Biological Chemistry</i> 255(11): 4980-4983, 1980.				
	AE	Burnette et al., "Western Blotting: Electrophoretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A," <i>Analytical Biochemistry</i> 112: 195-203, 1981.				
	AF	Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene," <i>Science</i> 230: 1132-1139, 1985.				
	AG	Dhut et al., "BCR-ABL and BCR Proteins: Biochemical Characterization and Localization," <i>Leukemia</i> 4(11): 745-750, 1990.				
	AH	Disis et al., "Existent T-Cell and Antibody Immunity to HER-2/neu Protein in Patients With Breast Cancer," <i>Cancer Res.</i> 54: 16-20, 1994.				
	AI	Falk et al., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules," <i>Nature</i> 351: 290-296, 1991.				
	AJ	Feller and de la Cruz, "Identifying antigenic T-cell sites," <i>Nature</i> 349: 720-721, 1991.				
✓	AK	Fisk et al., "Oligopeptide Induction of a Cytotoxic T Lymphocyte Response to HER-2/Neu Proto-oncogene in Vitro," <i>Cellular Immunology</i> 157:415-427, 1994.				
EXAMINER			DATE CONSIDERED			
<i>Karen J. Gamella</i>			7/3/01			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).						

FORM PTO-1449 (REV.7-80)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C8	APPLICATION NO. 09/167,516
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			APPLICANTS Martin A. Cheever and Mary L. Disis			
			FILING DATE October 6, 1998	GROUP ART UNIT 1642		
OCT 18 1999 U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL <i>Karen A. Gamble</i>	DOCUMENT NUMBER <i>PATENT & TRADEMARK OFFICE</i>	DATE	NAME		CLASS	SUBCLASS
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION
						YES NO
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>						
AA	Flanagan and Leder, "neu protooncogene fused to an immunoglobulin heavy chain gene requires immunoglobulin light chain for cell surface expression and oncogenic transformation," <i>Proc. Natl. Acad. Sci. USA</i> 85: 8057-8061, 1998.					
AB	Igelhart et al., "Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer," <i>Cancer Research</i> 50: 6701-6707, 1990.					
AC	Ioannides et al., "Antigens Recognized by T cells in Ovarian Cancer," in Abstracts of the Fourth International Conference of Anticancer Research, 21-25 Oct. 1992, Rethymnon, Crete, Greece, p. 1870.					
AD	Ioannides et al., "CTL Clones Isolated from Ovarian Tumor Infiltrating Lymphocytes can Recognize Peptides with Sequences Corresponding to the HER2/neu Gene Product," <i>FASEB Journal</i> 6: A1404, Abstract No. 2711, 1992.					
AE	Ioannides et al., "Cytotoxic T Cells Isolated From Ovarian Malignant Ascites Recognize a Peptide Derived From the HER-2/neu Proto-oncogene," <i>Cell. Immunol.</i> 151: 225-234, 1993.					
AF	Ioannides et al., "Cytotoxic T-Cell Clones Isolated from Ovarian Tumour Infiltrating Lymphocytes Recognize Common Determinants on Non-Ovarian Tumour Clones," <i>Scand. J. Immunol.</i> 37: 413-424, 1993.					
AG	Ioannides et al., "T-Cell Recognition of Oncogene Products: A New Strategy for Immunotherapy," <i>Molecular Carcinogenesis</i> 6: 77-82, 1992.					
AH	Ioannides, "Antigens and vaccines of female genital cancers (Meeting abstract)," Cancerlit Database Abstract No. ICDB/93690682, 1992.					
AI	Kallioniemi et al., "ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization," <i>Proc. Natl. Acad. Sci.</i> 89: 5321-5325, 1992.					
AJ	Kerns et al., "c-erbB-2 Expression In Breast Cancer Detected by Immunoblotting and Immunohistochemistry," <i>Journal of Histochemistry and Cytochemistry</i> 38(12): 1823-1830, 1990.					
AK	Laemmli, U., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," <i>Nature</i> 227: 680-685, 1970.					
EXAMINER <i>Karen A. Gamble</i>			DATE CONSIDERED <i>7/3/01</i>			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).						

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.448C8APPLICATION NO.
09/167,516

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE

October 6, 1998

GROUP ART UNIT

1642

OCT 18 1998

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER <i>(PRINT & TYPE IN BLOCK LETTERS)</i>	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-------------------	---	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
				YES NO

OTHER PRIOR ART (*Including Author, Title, Date, Pertinent Pages, Etc.*)

KAC	AA	Leitzel et al., "Elevated Soluble c-erbB2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients," <i>Journal of Clinical Oncology</i> 10(9): 1436-1443, 1992.
	AB	Lichtenstein et al., "Effects of .beta.-2 Microglobulin Anti-sense oligonucleotides on Sensitivity of HER2/neu Oncogene-Expressing and Nonexpressing Target Cells to Lymphocyte-Mediated Lysis," <i>Cellular Immunology</i> 141: 219-232, 1992.
	AC	Lippman, M., "Potential Contributions of Breast Cancer Biology to Management of Breast Cancer," <i>Advances in Oncology</i> 8(3): 26-28, 1992.
	AD	Maguire and Greene, "The neu (c-erbB-2) Oncogene," <i>Seminars in Oncology</i> 16(2): 148-155, 1989.
	AE	Margalit et al., "Prediction Of Immunodominant Helper T Cell Antigenic Sites From The Primary Sequence," <i>Journal of Immunology</i> 138(7): 2213-2229, 1987.
	AF	McGlynn et al., "Large-scale purification and characterisation of a recombinant epidermal growth-factor receptor protein-tyrosine kinase. Modulation of activity by multiple factors," <i>Eur. J. Biochem.</i> 207: 265-275, 1992.
	AG	McKenzie et al., "Induction of Antitumor Immunity by Immunization with a Vaccinia Virus Vector Expressing and Oncogene-encoded Product," in <i>Vaccines 88</i> , Cold Spring Harbor Laboratory, 1988, pp. 19-23.
	AH	Mietzner et al., "Purification and Characterization of the Major Iron-Regulated Protein Expressed By Pathogenic Neisseriae," <i>Journal of Experimental Medicine</i> 165: 1041-1057, 1987.
	AI	Mori et al., "In Vitro and in vivo Release of Soluble erbB-2 Protein from Human Carcinoma Cells," <i>Japanese Journal of Cancer Research</i> 81: 489-494, 1990.
	AJ	Paik et al., "Pathologic Findings From the National Surgical Adjuvant Breast and Bowel Project: Prognostic Significance of erbB-2 Protein Overexpression in Primary Breast Cancer," <i>Journal of Clinical Oncology</i> 8(1): 103-112, 1990.
✓	AK	Parker et al., "Sequence Motifs Important For Peptide Binding To The Human MHC Class I Molecule, HLA-A2," <i>Journal of Immunology</i> 149(11): 3580-3587, 1992.

EXAMINER

Karen A. Garza

DATE CONSIDERED

7/13/01

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)			U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 920010.448C8	APPLICATION NO. 09/167,516
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>			APPLICANTS Martin A. Cheever and Mary L. Disis			
			FILING DATE October 6, 1998	GROUP ART UNIT 1642		
U.S. PATENT DOCUMENTS						
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS IF APPROPRIATE
FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
OTHER PRIOR ART <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>						
<i>KAC</i>	AA		Press et al., "Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues," <i>Oncogene</i> 5: 953-962, 1990.			
	AB		Raines and Ross, "Platelet-derived Growth Factor. I. High Yields Purification and Evidence for Multiple Forms," <i>Journal of Biological Chemistry</i> 257(9): 5154-5159, 1982.			
	AC		Riberdy and Cresswell, "The Antigen-Processing Mutant T2 Suggests a Role for MHC-Linked Genes in Class-II-Antigen Presentation," <i>Journal of Immunology</i> 148(8):2586-2590, 1992.			
	AD		Rothbard and Taylor, "A sequence pattern common to T cell epitopes," <i>EMBO Journal</i> 7(1): 93-100, 1988.			
	AE		Semba et al., "A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma," <i>Proc. Natl. Acad. Sci. USA</i> 82: 6497-6501, 1985.			
	AF		Spies et al., "A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway," <i>Nature</i> 348: 744-747, 1990.			
	AG		Stern et al., "Oncogene Activation of p185(^{^neu}) Stimulates Tyrosine Phosphorylation In Vivo," <i>Molecular and Cellular Biology</i> 8(9): 3969-3973, 1988.			
	AH		Trowsdale et al., "Sequence encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters," <i>Nature</i> 348: 741-744, 1990.			
	AI		Weiner et al., "A point mutation in the neu oncogene mimics ligand induction of receptor aggregation," <i>Nature</i> 339: 230-231, 1989.			
	AJ		Wide, L., "Solid Phase Antigen-Antibody Systems," in <i>Radioimmunoassay Methods</i> , Kirkham and Hunter (eds.), 1973, pp. 405-412.			
<i>KAC</i>	AK		Wisdom, G.B., "Enzyme-Immunoassay," <i>Clin. Chem.</i> 22(8): 1243-1255, 1976.			
EXAMINER			DATE CONSIDERED			
<i>Karen J. Camello</i>			<i>7/3/01</i>			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).						

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
920010.448C8APPLICATION NO.
09/167,516

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OCT 18 1999

APPLICANTS

Martin A. Cheever and Mary L. Disis

FILING DATE

October 6, 1998

GROUP ART UNIT

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-------------------	-----------------	------	------	-------	----------	----------------------------

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
				YES NO

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AA	Yamamoto et al., "Similarity of protein encoded by the c-erb-B-2 gene to epidermal growth factor receptor," <i>Nature</i> 319: 230-234, 1986.
KAC	AB	Zabrecky et al., "The Extracellular Domain of p185/neu Is Released from the Surface of Human Breast Carcinoma Cells, SK-BR-3," <i>Journal of Biological Chemistry</i> 266(3): 1716-1720, 1991.
	AC	
	AD	
	AE	
	AF	
	AG	
	AH	
	AI	
	AJ	
	AK	

EXAMINER

Karen A. Gamble

DATE CONSIDERED

7/13/01

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).